We want to ensure optimum use of our website for you, and to continually improve our website. Therefore, we work with selected partners (e.g. Pardot). You can revoke your voluntary consent at any time. You can find further information and setting options under „Configure“ and in our data protection information.
PRESS RELEASE Stockholm, May 3, 2007
Elekta, world leader in advanced radiation therapy, comprehensive cancer management and non-invasive treatment of brain disorders, have today finalized the acquisition of 3D Line Medical Systems S.r.l.
Through this acquisition, Elekta adds a highly qualified R&D group specialized in stereotactic radiosurgery and dynamic IMRT treatments as well as a product portfolio of advanced equipment and treatment planning software systems for performing radiation therapy with extreme precision and optimized dose distribution.
The company has 35 employees and consultants, of whom most are based in Milan, Italy. Among the 3D Line technologies commercially available today, are the ERGO++, a specialized treatment planning system for stereotactic radiation therapy and dynamic IMRT and also the DYNART™ series of micro-sized multi leaf collimators. In 2006, 3D Line’s net sales totaled EUR 6 M with a moderate profit.
Elekta will pay EUR 10 M in cash for assets in 3D Line Medical Systems related to radiation therapy and up to a maximum of EUR 8 M, based on future performance over the coming 3 years. Elekta expects to consolidate 3D Line into its accounts from May 1, 2007.
“3D Line’s current products as well as the R&D pipeline fit extremely well into the Elekta Group and the acquisition is an important step in the further advancement of radiation therapy”, says Tomas Puusepp, President and CEO of Elekta. “3D Line’s cutting edge technology for dynamic beam shaping, arc treatment and stereotactic treatment planning is an excellent addition to Elekta’s world-leading solutions for advanced radiation therapy and with the increased global sales reach within Elekta, we will be able to exploit the increasing demand for these products”, Tomas Puusepp concludes.